Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Most Generics Listed in 2006 Available in All Specifications
July 17, 2006
- Original Makers Preparing for Competition with Generics
July 17, 2006
- TOPICS 2 articles
July 17, 2006
- Oncology Div. Preparing to Launch Nexavar: Bayer Yakuhin
July 10, 2006
- REGULATORY NEWS IN BRIEF
July 10, 2006
- R&D Management Company More Efficient Than Council: Eisai
July 10, 2006
- Pfizer to Sell CHC Business to J&J for US$16.6 Bil.
July 10, 2006
- Eisai Licenses SERM to Radius
July 10, 2006
- OTC Version of Teijin's Aftach Recommended for Approval
July 10, 2006
- Takeda Ordered to Pay \57 Bil. in Additional Taxes
July 10, 2006
- SELF-MEDICATION NEWS IN BRIEF
July 10, 2006
- Shareholders Express Concern over Future Strategies
July 10, 2006
- R&D NEWS IN BRIEF
July 10, 2006
- BUSINESS NEWS IN BRIEF
July 10, 2006
- Highlights of 42nd ASCO Meeting Announced by Matson Jack
July 10, 2006
- NEW PRODUCTS
July 10, 2006
- New Clinical Study on Pancreatic Cancer Planned: JACCRO
July 10, 2006
- Differences between Original Drugs and Generics Do Not Mean Problems with Generics: Prof. Ogata
July 10, 2006
- BI"Sifrol Effective for RLS in Japanese Patients
July 10, 2006
- Generics Should Use Only Generic Name: Prof. Matsuyama
July 10, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…